Endo International plc (ENL) Got Some Good News

According to The Fly, in a new note to investors today, an analyst has provided a rating update for the Healthcare company, Endo International plc (ENL). Canaccord Genuity’s analyst Dewey Steadman upgraded ENL to Buy.

According to, Steadman is a 1-star analyst with an average return of -2.4% and a 34.2% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Amneal Pharmaceuticals Inc, ANI Pharmaceuticals Inc, and Pacira Pharmaceuticals.

Read also: Why OncoSec Medical (ONCS) Stock Crashed Today

The the analyst consensus on Endo International plc is currently a Moderate Buy rating.

Based on Endo International plc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$226 million. In comparison, last year the company had a GAAP net loss of C$121 million.

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The company operates through the following segments: U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals and International Pharmaceuticals.